The FDA today posted a warning letter sent to LeMaitre (LMAT), dated August 11, following an inspection of the company’s North Brunswick, New Jersey facility. The inspection revealed that LeMaitre’s Artegraft collagen vascular grafts are adulterated. Shares of LeMaitre closed Tuesday down 2% to $95.28.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LMAT: